Support of State and Private Institutions for Biomedical Start-ups in Russia

Cover Page

Cite item

Full Text

Abstract

This paper describes the differences between biomedical start-ups with state support and start-ups with support provided by private market participants in Russia as a country with limited private investments. Based on the sample of Skolkovo biomedical start-ups, we analyse ownership and management characteristics of start-ups as well as the performance of companies supported by these two types of institutions.

To compare start-ups supported from different sources, the sample of biomedical companies is divided into four clusters based on the presence of state and/or private support. The results of cluster characterization indicate that start-ups with different types of support vary significantly in ownership concentration, share of managerial ownership, gender diversity and CEO experience.
Although tests for differences among the groups’ mean values showed the insignificance of performance variation among clusters, start-ups with private funding in the sample were mostly smaller-sized companies with fewer patentsand employees. At the same time, start-ups that were supported from both private and state sources performed better on average in the number of employees and patents and the presence of revenue. Although the causal relationship between the type of support and start-up performance is not investigated in this paper, our results suggest the importance of the synergy of state and private support for biomedical start-up performance in Russia.

Besides contributing to the literature on start-up support in emerging markets, this paper is, as far as we know, one of the first academic studies to provide insights into the market of Russian biotech start-ups.

About the authors

O. Guseva

Higher School of Economics

Author for correspondence.
Email: olga.gusevaa@gmail.com
ORCID iD: 0000-0001-6910-3102
Russian Federation, Moscow

References

  1. International Monetary Fund. World Economic Outlook Update, June 2020. Available from: https://www.imf.org/en/Publications/WEO/Issues/2020/06/24/WEOUpdateJune2020
  2. Kuchler H., Mooney A. Pharma industry seizes on pandemic as a shot at redemption. Financial Times. 2020 Jul 5.
  3. Manuilova A. Drug market grew on virus (Рынок лекарств вырос на вирусе). Kommersant. 2020 Jun 18.
  4. Kravchenko E. Which Russian industries were hit most by coronavirus pandemic (Какие отрасли российской промышленности пострадали от пандемии коронавируса сильнее всего). Forbes. 2020 Jul 1.
  5. Russian Venture Capital Association. Private equity and venture capital investments market review in 2018 (Обзор рынка прямых и венчурных инвестиций за 2018 год). Available from: http://www.rvca.ru/rus/resource/library/rvca-yearbook/
  6. KPMG. Venture Pulse: Q4’18 Global analysis of venture funding. Available from: https://assets.kpmg/content/dam/kpmg/xx/pdf/2019/01/kpmg-venture-pulse-q4-2018.pdf
  7. Lazonick W., Tulum Ö. US biopharmaceutical finance and the sustainability of the biotech business model. Research Policy. 2011;40(9):1170–1187.
  8. Dua A., Mahajan D., Oyer L., Ramaswamy S. US small-business recovery after the COVID-19 crisis. McKinsey & Company. 2020 Jul 7.
  9. Thurik R., Wennekers S. Entrepreneurship, small business and economic growth. Journal of Small Business and Enterprise Development. 2004;11(1):140–149.
  10. Van Stel A., Carree M., Thurik R. The effect of entrepreneurial activity on national economic growth. Small Business Economics. 2005;24(3):311–321.
  11. Acs Z.J., Estrin S., Mickiewicz T., Szerb L. Entrepreneurship, institutional economics, and economic growth: an ecosystem perspective. Small Business Economics. 2018;51(2):501–514.
  12. Portincaso M., de la Tour A., Soussan P. The Dawn of the Deep Tech Ecosystem. BCG.com. 2019 Mar 14. Available from: https://www.bcg.com/publications/2019/dawn-deep-tech-ecosystem.aspx
  13. Dsight. Venture Russia. 2018 results (Венчурная Россия. Результаты 2018 года). Available from: http://dsight.ru/company/news/Исследование%20Dsight%20Венчурная%20Россия%20-%20итоги%202018%20года.pdf
  14. Nosella A., Petroni G., Verbano C. How do Italian biotech startups survive? Journal of Business Chemistry. 2006;3(2).
  15. Schwienbacher A. A theoretical analysis of optimal financing strategies for different types of capital-constrained entrepreneurs. Journal of Business Venturing. 2007;22(6):753–781.
  16. Drover W., Wood M., Fassin Y. Take the money or run? Investors’ ethical reputation and entrepreneurs’ willingness to partner. Journal of Business Venturing. 2014;29(6):723–740.
  17. Islam M., Fremeth A., Marcus A. Signaling by early stage startups: US government research grants and venture capital funding. Journal of Business Venturing. 2018;33(1):35–51.
  18. Knockaert M., Clarysse B., Wright M. The extent and nature of heterogeneity of venture capital selection behaviour in new technology-based firms. R&D Management. 2010;40:357–371.
  19. Malmström M., Voitkane A., Johansson J., Wincent J. What do they think and what do they say? Gender bias, entrepreneurial attitude in writing and venture capitalists’ funding decisions. Journal of Business Venturing Insights. 2020;13.
  20. Shane S., Cable D. Network ties, reputation, and the financing of new ventures. Management Science. 2002;48(3):364–381.
  21. Afful-Dadzie E., Afful-Dadzie A. A decision making model for selecting start-up businesses in a government venture capital scheme. Management Decision. 2016;54(3).
  22. Uzuegbunam I., Liao Y., Pittaway L., Jolley G. Human capital, intellectual capital, and government venture capital. Journal of Entrepreneurship and Public Policy. 2017;6(3):359–374.
  23. Pahnke E., Katila R., Eisenhardt K. Who takes you to the dance? How partners’ institutional logics influence innovation in young firms. Administrative Science Quarterly. 2015;60(4):596–633.
  24. Samila S., Sorenson O. Venture capital, entrepreneurship, and economic growth. The Review of Economics and Statistics. 2011;93(1):338–349.
  25. Puri M., Zarutskie R. On the life cycle dynamics of venture-capital- and non-venture-capital-financed firms. Journal of Finance. 2012;67(6):2247–2293.
  26. Doh S., Kim B. Government support for SME innovations in the regional industries: The case of government financial support program in South Korea. Research Policy. 2014;43(9):1557–1569.
  27. Keller M., Block F. Explaining the transformation in the US innovation system: The impact of a small government program. Socio-Economic Review. 2012;11(4):629–656.
  28. Luukkonen T., Deschryvere M., Bertoni F. The value added by government venture capital funds compared with independent venture capital funds. Technovation. 2013;33(4–5):154–162.
  29. Grilli L., Murtinu S. Government, venture capital and the growth of European high-tech entrepreneurial firms. Research Policy. 2014;43(9):1523–1543.
  30. Fleming L., Greene H., Li G., Marx M., Yao D. Government-funded research increasingly fuels innovation. Science. 2019;364(6446):1139.
  31. Harwell M.R., Rubinstein E.N., Hayes W.S., Olds C.C. Summarizing Monte Carlo results in methodological research: The one- and two-factor fixed effects ANOVA cases. Journal of Educational Statistics. 1992;17(4):315–339.
  32. Lix L.M., Keselman J.C., Keselman H.J. Consequences of assumption violations revisited: A quantitative review of alternatives to the one-way analysis of variance F test. Review of Educational Research. 1996;66(4):579–619.
  33. Guseva O., Stepanova A. Owners and CEOs of startups: Evidence from Russia. Journal of Corporate Finance Research / Корпоративные финансы. 2019;13(1):107–119.
  34. Kwapisz A., Hechavarría D.M. Women don’t ask: An investigation of start-up financing and gender. Venture Capital. 2018;20(2):159–190.
  35. Cumming D.J., Grilli L., Murtinu S. Governmental and independent venture capital investments in Europe: A firm-level performance analysis. Journal of Corporate Finance. 2017;42:439–459.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Guseva O.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.